Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The US Patent and Trademark Office has granted a new patent 7,846,744, entitled 'Methods of Identifying Anti-Inflammatory Compounds,' for Virdante's Sialic Switch technology for improving the anti-inflammatory activity of antibody-based drugs to treat autoimmune and inflammatory disorders.
Subscribe to our email newsletter
Virdante has exclusively licensed the Sialic Switch technology from The Rockefeller University and established a strategic research alliance with Jeffrey Ravetch laboratory.
The new US patent covers the usage of human receptor DC-SIGN (or mouse SIGN-R1) to screen for drugs that either suppress or activate anti-inflammatory activity.
Virdante CEO John Ripple said that this patent provides important validation for their proprietary Sialic Switch technology, and provides an additional level of protection for the novel antibody-based drug development programs ongoing at Virdante.
"We are focused on continuing to advance our lead sIVIG development candidate toward clinical trials as the first step in achieving human proof of concept for the broad applications of our Sialic Switch technology," Ripple said.